Synta’s Ganetespib Could Break The Hsp90i Curse
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
If ganetespib succeeds in Phase III, it could become the first new treatment for advanced lung adenocarcinoma in a decade, but the heat shock protein class has yet to produce a winner.